CLL treatment landscape, Available treatment options for a R/R CLL, CLL-321 data, incl target patient
To equip healthcare professionals with the latest knowledge on novel therapeutic strategies for managing patients with Chronic Lymphocytic Leukemia.
Participants will be able to differentiate between first-line, second-line, and relapsed/refractory treatment options for Chronic Lymphocytic Leukemia.
Participants will be able to explain the rationale behind using BTK inhibitors in CLL treatment.
Participants will be able to identify the various targeted therapies currently approved for CLL.

FREE
Free
11 Nov 2025 To 11 Nov 2025
06:00 PM To 07:00 PM
Certificate Available
Online